Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 16;8(7):e021346.
doi: 10.1136/bmjopen-2017-021346.

Mobile therapeutic attention for treatment-resistant schizophrenia (m-RESIST): a prospective multicentre feasibility study protocol in patients and their caregivers

Anna Alonso-Solís #  1   2 , Katya Rubinstein #  3 , Iluminada Corripio  1   2 , Erika Jaaskelainen  4   5 , Annika Seppälä  4   5 , Vincenzo Alberto Vella  6 , Johanna Caro-Mendivelso  6 , Asaf Caspi  3 , Matti Isohanni  4   5 , Zsolt Unoka  7 , Shenja Van der Graff  8 , Kinga Farkas  7 , Elena Huerta-Ramos  2   9 , Silvia Marcó-García  9 , Matthias Stevens  10 , Tanguy Coenen  10 , Margarita Hospedales  11 , Jesús Berdún  11 ; m-Resist group; Eva M Grasa  1   2
Collaborators, Affiliations

Mobile therapeutic attention for treatment-resistant schizophrenia (m-RESIST): a prospective multicentre feasibility study protocol in patients and their caregivers

Anna Alonso-Solís et al. BMJ Open. .

Abstract

Introduction: Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia. In the European Union, approximately 40% of people with schizophrenia have TRS. Factors such as the persistence of positive symptoms or higher risk of comorbidities leave clinicians with a complex scenario when treating these patients. Intervention strategies based on mHealth have demonstrated their ability to support and promote self-management-based strategies. Mobile therapeutic attention for treatment-resistant schizophrenia (m-RESIST), an innovative mHealth solution based on novel technology and offering high modular and flexible functioning, has been developed specifically for patients with TRS and their caregivers. As intervention in TRS is a challenge, it is necessary to perform a feasibility study before the cost-effectiveness testing stage.

Methods and analysis: This manuscript describes the protocol for a prospective multicentre feasibility study in 45 patients with TRS and their caregivers who will be attended in the public health system of three localities: Hospital Santa Creu Sant Pau (Spain), Semmelweis University (Hungary) and Gertner Institute & Sheba Medical Center (Israel). The primary aim is to investigate the feasibility and acceptability of the m-RESIST solution, configured by three mHealth tools: an app, wearable and a web-based platform. The solution collects data about acceptability, usability and satisfaction, together with preliminary data on perceived quality of life, symptoms and economic variables. The secondary aim is to collect preliminary data on perceived quality of life, symptoms and economic variables.

Ethics and dissemination: This study protocol, funded by the Horizon 2020 Programme of the European Union, has the approval of the ethics committees of the participating institutions. Participants will be fully informed of the purpose and procedures of the study, and signed inform consents will be obtained. The results will be published in peer-reviewed journals and presented in scientific conferences to ensure widespread dissemination.

Trial registration number: NCT03064776; Pre-results.

Keywords: feasibility; mhealth; mobile device based intervention; psychosis; treatment-resistant schizophrenia.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
mHealth tools of the m-RESIST solution. m-RESIST, mobile therapeutic attention for treatment-resistant schizophrenia.
See this image and copyright information in PMC

References

    1. Wittchen HU, Jacobi F, Rehm J, et al. . The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:655–79. 10.1016/j.euroneuro.2011.07.018 - DOI - PubMed
    1. Elkis H, Buckley PF. Treatment-Resistant Schizophrenia. Psychiatr Clin North Am 2016;39:239–65. 10.1016/j.psc.2016.01.006 - DOI - PubMed
    1. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001;50:898–911. 10.1016/S0006-3223(01)01271-9 - DOI - PubMed
    1. Kennedy JL, Altar CA, Taylor DL, et al. . The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 2014;29:63–76. 10.1097/YIC.0b013e32836508e6 - DOI - PubMed
    1. de Silva J, Hanwella R, de Silva VA. Direct and indirect cost of schizophrenia in outpatients treated in a tertiary care psychiatry unit. Ceylon Med J 2012;57:14–18. 10.4038/cmj.v57i1.4195 - DOI - PubMed

Publication types

MeSH terms

Associated data